239 related articles for article (PubMed ID: 15076166)
1. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
[TBL] [Abstract][Full Text] [Related]
2. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitors: a new mechanism of action.
Peng H; Carretero OA; Vuljaj N; Liao TD; Motivala A; Peterson EL; Rhaleb NE
Circulation; 2005 Oct; 112(16):2436-45. PubMed ID: 16216963
[TBL] [Abstract][Full Text] [Related]
4. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.
Peng H; Carretero OA; Brigstock DR; Oja-Tebbe N; Rhaleb NE
Hypertension; 2003 Dec; 42(6):1164-70. PubMed ID: 14581293
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.
Rhaleb NE; Peng H; Yang XP; Liu YH; Mehta D; Ezan E; Carretero OA
Circulation; 2001 Jun; 103(25):3136-41. PubMed ID: 11425781
[TBL] [Abstract][Full Text] [Related]
6. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
Liu YH; D'Ambrosio M; Liao TD; Peng H; Rhaleb NE; Sharma U; André S; Gabius HJ; Carretero OA
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H404-12. PubMed ID: 19098114
[TBL] [Abstract][Full Text] [Related]
7. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
8. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension.
Lin CX; Rhaleb NE; Yang XP; Liao TD; D'Ambrosio MA; Carretero OA
Am J Physiol Heart Circ Physiol; 2008 Sep; 295(3):H1253-H1261. PubMed ID: 18641275
[TBL] [Abstract][Full Text] [Related]
9. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
[TBL] [Abstract][Full Text] [Related]
10. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
[TBL] [Abstract][Full Text] [Related]
11. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
12. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.
Sharma U; Rhaleb NE; Pokharel S; Harding P; Rasoul S; Peng H; Carretero OA
Am J Physiol Heart Circ Physiol; 2008 Mar; 294(3):H1226-32. PubMed ID: 18178715
[TBL] [Abstract][Full Text] [Related]
13. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.
Liao TD; Yang XP; D'Ambrosio M; Zhang Y; Rhaleb NE; Carretero OA
Hypertension; 2010 Feb; 55(2):459-67. PubMed ID: 20026760
[TBL] [Abstract][Full Text] [Related]
14. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Perego C; Perego L; Mancini M; Leopizzi M; Corradi B; Perlini S; Zerbini G; Stella A
Clin Sci (Lond); 2009 Oct; 118(3):211-20. PubMed ID: 20310083
[TBL] [Abstract][Full Text] [Related]
15. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction.
Yang F; Yang XP; Liu YH; Xu J; Cingolani O; Rhaleb NE; Carretero OA
Hypertension; 2004 Feb; 43(2):229-36. PubMed ID: 14691195
[TBL] [Abstract][Full Text] [Related]
16. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
17. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats.
Cingolani OH; Yang XP; Liu YH; Villanueva M; Rhaleb NE; Carretero OA
Hypertension; 2004 May; 43(5):1067-73. PubMed ID: 15023934
[TBL] [Abstract][Full Text] [Related]
19. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
Cavasin MA; Rhaleb NE; Yang XP; Carretero OA
Hypertension; 2004 May; 43(5):1140-5. PubMed ID: 15037553
[TBL] [Abstract][Full Text] [Related]
20. N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats.
González GE; Rhaleb NE; Nakagawa P; Liao TD; Liu Y; Leung P; Dai X; Yang XP; Carretero OA
Clin Sci (Lond); 2014 Jan; 126(1):85-94. PubMed ID: 23834332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
